Clinical Trial Update: An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor [Phase 2]

View source ↗

Summary

Open-label Phase II trial evaluating the combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in metastatic melanoma refractory to BRAF inhibitors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-12-12